May 2001

From Yale University

New clinical program development fund awards $17.6 million in grants for Yale-New Haven Medical Center

New research at Yale in cancer, brain disorders, cardiovascular disease, developmental disorders and organ transplantation will be advanced with $17.6 million in grants from the New Clinical Program Development Fund (the Fund).

The Fund is a joint initiative created by the Yale-New Haven Health System, Yale-New Haven Hospital and Yale University School of Medicine to support the development and implementation of new clinical programs in the Medical Center (Yale University, Yale School of Medicine and Yale-New Haven Hospital working in cooperation).

According to Richard Edelson, M.D., deputy chair of the Fund and chair of dermatology at Yale, one of the goals of the initiative is to enhance the quality and scope of clinical services available at the Medical Center. The Fund will also be used to help achieve highly ranked national status in the five designated clinical priority areas.

"We want to position the Medical Center at the top of the field in as many target areas as possible," Edelson said. "Investment from the Fund is intended to allow these programs to push the envelope and in some cases to define the frontier."

Peter Herbert, M.D, chief of staff at Yale-New Haven Hospital and the Fund's co-chair, said the Fund invites proposals that present innovative approaches to diagnosing, treating and/or preventing diseases or disorders in the designated clinical areas. "We hope support from the Fund will result in the long term establishment of programs that have strong clinical applications with an appropriate research base," he said.

The clinical areas of funded proposals and physician applicants include:

Brain Disorders

* Clinical Neuroscience Center for Epilepsy and Neurovascular Diseases, Dennis Spencer, M.D.
* Yale-New Haven Medical Center Brain Tumor Center, Joseph Piepmeier, M.D.

Cancer

* Transimmunization: A New Method for Treatment of Graft vs. Host Disease, Prevention of Graft Rejection and Immunization against Tumor Antigens, Michael Girardi, M.D.
* Expansion of the Yale Cancer Center Clinical Trials Office, Leonard Farber, M.D.
* New Infrastructure and Organization for the NCI Approved Yale Comprehensive Cancer Center, Vincent T. DeVita, Jr., M.D.
* Innovations of Head and Neck Management, Clarence Sasaki, M.D.

Cardiovascular Disease

* Yale New Haven Medical Center Endovascular Center, Bauer Sumpio, M.D.
* Integrated Program for the Treatment of End Stage Heart Disease, Barry Zaret, M.D.
* Endovascular Brachytherapy, Kenneth B. Roberts, M.D.

Developmental Disorders

* Yale New Haven Medical Center Oncofertility Center, Steven Palter, M.D.

Organ Replacement

* Transplantation, Marc Lorber, M.D.

The fund received 23 proposals in the first round with requests totaling $69.1 million and awarded $17.6 of the $18 million available. Two committees, co-chaired by Edelson and Herbert, and comprised of both School of Medicine and Hospital representatives, reviewed each proposal and made recommendations to Dean of Yale School of Medicine, David Kessler, M.D. and Yale-New Haven Hospital President and CEO, Joseph Zaccagnino, who made the final determinations.

The Fund is now calling for a second round of applications. In 2001, $11.5 million is available for funding support and the five clinical priority areas will remain the same. The application process begins with the submission of a two-page letter of intent that will be reviewed by the Fund's planning and development committees and the Strategic Development Committee of the Yale Medical Group. The Strategic Development Committee will help coordinate clinical initiatives between the Yale Medical Group and the Fund and ensure consistency with the school's clinical strategic plan.












This article comes from Science Blog. Copyright 2004
http://www.scienceblog.com/community

Archives 2001 F